State-of-the-art human gene therapy: Part I. Gene delivery technologies

Discovery Medicine

Volumn 18, Issue 97, 2014, Pages 67-77

  Wang, Dan ^a   Gao, Guangping ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALIPOGENE TIPARVOVEC; CD19 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERPESVIRUS VECTOR; LENTIVIRUS VECTOR; LIPOPROTEIN LIPASE; PLASMID DNA; RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR; TALIMOGENE LAHERPAREPVEC; TOLL LIKE RECEPTOR 9; VIRUS GLYCOPROTEIN;

ADRENOLEUKODYSTROPHY; AGE RELATED MACULAR DEGENERATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL BASED GENE THERAPY; DNA VECTOR; EX VIVO GENE TRANSFER; GENE EXPRESSION REGULATION; GENE THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPOPROTEINEMIA TYPE 1; IMMUNOTOXICITY; INFLUENZA; MELANOMA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; ONCOLYTIC VIROTHERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLURIPOTENT STEM CELL; RECOMBINANT DNA TECHNOLOGY; SAFETY; STEM CELL TRANSPLANTATION; TRANSGENE; TRANSPOSON; VACCINATION; VIRAL GENE DELIVERY SYSTEM; GENE TRANSFER; GENE VECTOR;

GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS;

EID: 84916928035     PISSN: 15396509     EISSN: 19447930     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Aiuti A, Cattaneo F, Galimberti S, BenninghoffU, Cassani B, Callegaro L, Scaramuzza S, AndolfiG, Mirolo M, Brigida I, Tabucchi A, Carlucci F, Eibl M, Aker M, Slavin S, Al-Mousa H, Al Ghonaium A, Ferster A, Duppenthaler A, Notarangelo L, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 360(5):447-458, 2009.
2. Argyros O, Wong SP, Harbottle RP. Non-viral episomal modification of cells using S/MAR elements. Expert Opin Biol Ther 11(9):1177-1191, 2011.
3. Balazs AB, Bloom JD, Hong CM, Rao DS, Baltimore D. Broad protection against influenza infection by vectored immunoprophylaxis in mice. Nat Biotechnol 31(7):647-652, 2013.
4. Balazs AB, Chen J, Hong CM, Rao DS, Yang L, Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 481(7379):81-84, 2012.
5. Balazs AB, West AP, Jr. Antibody gene transfer for HIV immunoprophylaxis. Nat Immunol 14(1):1-5, 2013.
6. Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A, Meyer J, Huddart R, Smith K, Townsend R, Brown A, Antrobus R, Ammendola V, Naddeo M, O'hara G, Willberg C, Harrison A, Grazioli F, Esposito ML, Siani L, et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 4(115):115ra111, 2012.
7. Barton GM, Kagan JC, Medzhitov R. Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nat Immunol 7(1):49-56, 2006.
8. Bigger BW, Wynn RF. Novel approaches and mechanisms in hematopoietic stem cell gene therapy. Discov Med 17(94), 2014.
9. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I, Vidaud M, Abel U, Dal-Cortivo L, Caccavelli L, Mahlaoui N, Kiermer V, Mittelstaedt D, Bellesme C, Lahlou N, Lefrere F, Blanche S, Audit M, Payen E, Leboulch P, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326(5954):818-823, 2009.
10. Cerullo V, Pesonen S, Diaconu I, Escutenaire S, Arstila PT, Ugolini M, Nokisalmi P, Raki M, Laasonen L, Sarkioja M, Rajecki M, Kangasniemi L, Guse K, Helminen A, Ahtiainen L, Ristimaki A, Raisanen-Sokolowski A, Haavisto E, Oksanen M, Karli E, et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res 70(11):4297-4309, 2010.
11. Choi IK, Yun CO. Recent developments in oncolytic adenovirus-based immunotherapeutic agents for use against metastatic cancers. Cancer Gene Ther 20(2):70-76, 2013.
12. Duque S, Joussemet B, Riviere C, Marais T, Dubreil L, Douar AM, Fyfe J, Moullier P, Colle MA, Barkats M. Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther 17(7):1187-1196, 2009.
13. Ellis J, Baum C, Benvenisty N, Mostoslavsky G, Okano H, Stanford WL, Porteus M, Sadelain M. Benefits of utilizing gene-modified iPSCs for clinical applications. Cell Stem Cell 7(4):429-430, 2010.
14. Ertl HC. Progress in the development of hepatitis C virus vaccines. Mol Ther 20(4):697-698, 2012.
15. Flotte TR. Birth of a new therapeutic platform: 47 years of adeno-associated virus biology from virus discovery to licensed gene therapy. Mol Ther 21(11):1976-1981, 2013.
16. Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 27(1):59-65, 2009.
17. Gao G, Sena-Esteves M. Introducing genes into mammalian cells: Viral vectors. In: Molecular Cloning. 4th edition. MR Green, JR Sambrook (Eds.). pp1209-1330. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, NY, USA, 2012.
18. Gao G, Vandenberghe LH, Wilson JM. New recombinant serotypes of AAV vectors. Curr Gene Ther 5(3):285-297, 2005.
19. Giacca M, Zacchigna S. Virus-mediated gene delivery for human gene therapy. J Control Release 161(2):377-388, 2012.
20. Gill DR, Pringle IA, Hyde SC. Progress and prospects: the design and production of plasmid vectors. Gene Ther 16(2):165-171, 2009.
21. Goins WF, Huang S, Cohen JB, Glorioso JC. Engineering HSV-1 Vectors for Gene Therapy. Methods Mol Biol 1144:63-79, 2014.
22. Goss JR, Krisky D, Wechuck J, Wolfe D. Herpes simplex virus-based nerve targeting gene therapy in pain management. J Pain Res 7:71-79, 2014.
23. Hacein-Bey-Abina S, Hauer J, Lim A, Picard C, Wang GP, Berry CC, Martinache C, Rieux-Laucat F, Latour S, Belohradsky BH, Leiva L, Sorensen R, Debre M, Casanova JL, Blanche S, Durandy A, Bushman FD, Fischer A, Cavazzana-Calvo M. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 363(4):355-364, 2010.
24. Hackett PB, Jr, Aronovich EL, Hunter D, Urness M, Bell JB, Kass SJ, Cooper LJ, Mcivor S. Efficacy and safety of Sleeping Beauty transposon-mediated gene transfer in preclinical animal studies. Curr Gene Ther 11(5):341-349, 2011.
25. Hackett PB, Largaespada DA, Switzer KC, Cooper LJ. Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy. Transl Res 161(4):265-283, 2013.
26. Jazwa A, Florczyk U, Jozkowicz A, Dulak J. Gene therapy on demand: Site specific regulation of gene therapy. Gene 525(2):229-238, 2013.
27. Jethwa H, Adami AA, Maher J. Use of gene-modified regulatory T-cells to control autoimmune and alloimmune pathology: is now the right time?. Clin Immunol 150(1):51-63, 2014.
28. Jin L, Zeng X, Liu M, Deng Y, He N. Current Progress in Gene Delivery Technology Based on Chemical Methods and Nano-carriers. Theranostics 4(3):240-255, 2014.
29. Johnson PR, Schnepp BC, Zhang J, Connell MJ, Greene SM, Yuste E, Desrosiers RC, Clark KR. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med 15(8):901-906, 2009.
30. Kaeppel C, Beattie SG, Fronza R, Van Logtenstein R, Salmon F, Schmidt S, Wolf S, Nowrouzi A, Glimm H, Von Kalle C, Petry H, Gaudet D, Schmidt M. A largely random AAV integration profile after LPLD gene therapy. Nat Med 19(7):889-891, 2013.
31. Kay MA. State-of-the-art gene-based therapies: the road ahead. Nat Rev Genet 12(5):316-328, 2011.
32. Kay MA, He CY, Chen ZY. A robust system for production of minicircle DNA vectors. Nat Biotechnol 28(12):1287-1289, 2010.
33. Kerkar SP. "Model T" Cells: A Time-Tested Vehicle for Gene Therapy. Front Immunol 4:304, 2013.
34. Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol 10(5):267-276, 2013.
35. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, Maric I, Raffeld M, Nathan DA, Lanier BJ, Morgan RA, Rosenberg SA. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116(20):4099-4102, 2010.
36. Kotin RM. Large-scale recombinant adeno-associated virus production. Hum Mol Genet 20(R1):R2-6, 2011.
37. Lasaro MO, Ertl HC. New insights on adenovirus as vaccine vectors. Mol Ther 17(8):1333-1339, 2009.
38. Lehrman S. Virus treatment questioned after gene therapy death. Nature 401(6753):517-518, 1999.
39. Li L, Krymskaya L, Wang J, Henley J, Rao A, Cao LF, Tran CA, Torres-Coronado M, Gardner A, Gonzalez N, Kim K, Liu PQ, Hofer U, Lopez E, Gregory PD, Liu Q, Holmes MC, Cannon PM, Zaia JA, Digiusto DL. Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc finger nucleases. Mol Ther 21(6):1259-1269, 2013.
40. Li W, Asokan A, Wu Z, Van Dyke T, Diprimio N, Johnson JS, Govindaswamy L, Agbandje-Mckenna M, Leichtle S, Redmond DE, Jr., Mccown TJ, Petermann KB, Sharpless NE, Samulski RJ. Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Mol Ther 16(7):1252-1260, 2008.
41. Lisa Li H, Nakano T, Hotta A. Genetic correction using engineered nucleases for gene therapy applications. Dev Growth Differ 56(1):63-77, 2014.
42. Lisowski L, Dane AP, Chu K, Zhang Y, Cunningham SC, Wilson EM, Nygaard S, Grompe M, Alexander IE, Kay MA. Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature 506(7488):382-386, 2014.
43. Lombardo A, Genovese P, Beausejour CM, Colleoni S, Lee YL, Kim KA, Ando D, Urnov FD, Galli C, Gregory PD, Holmes MC, Naldini L. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol 25(11):1298-1306, 2007.
44. Lu J, Zhang F, Kay MA. A mini-intronic plasmid (MIP): a novel robust transgene expression vector in vivo and in vitro. Mol Ther 21(5):954-963, 2013.
45. Mali P, Esvelt KM, Church GM. Cas9 as a versatile tool for engineering biology. Nat Methods 10(10):957-963, 2013.
46. Manservigi R, Argnani R, Marconi P. HSV Recombinant Vectors for Gene Therapy. Open Virol J 4:123-156, 2010.
47. Masat E, Pavani G, Mingozzi F. Humoral immunity to AAV vectors in gene therapy: challenges and potential solutions. Discov Med 15(85):379-389, 2013.
48. Mayrhofer P, Schleef M, Jechlinger W. Use of minicircle plasmids for gene therapy. Methods Mol Biol 542:87-104, 2009.
49. Miest TS, Cattaneo R. New viruses for cancer therapy: meeting clinical needs. Nat Rev Microbiol 12(1):23-34, 2014.
50. Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 12(5):341-355, 2011.
51. Mingozzi F, High KA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 122(1):23-36, 2013.
52. Nagabhushan Kalburgi S, Khan NN, Gray SJ. Recent gene therapy advancements for neurological diseases. Discov Med 15(81):111-119, 2013.
53. Naldini L. Ex vivo gene transfer and correction for cell-based therapies. Nat Rev Genet 12(5):301-315, 2011.
54. Papapetrou EP, Lee G, Malani N, Setty M, Riviere I, Tirunagari LM, Kadota K, Roth SL, Giardina P, Viale A, Leslie C, Bushman FD, Studer L, Sadelain M. Genomic safe harbors permit high beta-globin transgene expression in thalassemia induced pluripotent stem cells. Nat Biotechnol 29(1):73-78, 2011.
55. Payen E, Colomb C, Negre O, Beuzard Y, Hehir K, Leboulch P. Lentivirus vectors in beta-thalassemia. Methods Enzymol 507:109-124, 2012.
56. Pien GC, Basner-Tschakarjan E, Hui DJ, Mentlik AN, Finn JD, Hasbrouck NC, Zhou S, Murphy SL, Maus MV, Mingozzi F, Orange JS, High KA. Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors. J Clin Invest 119(6):1688-1695, 2009.
57. Provasi E, Genovese P, Lombardo A, Magnani Z, Liu PQ, Reik A, Chu V, Paschon DE, Zhang L, Kuball J, Camisa B, Bondanza A, Casorati G, Ponzoni M, Ciceri F, Bordignon C, Greenberg PD, Holmes MC, Gregory PD, Naldini L, et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat Med 18(5):807-815, 2012.
58. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol 30(7):658-670, 2012.
59. Sakuma T, Barry MA, Ikeda Y. Lentiviral vectors: basic to translational. Biochem J 443(3):603-618, 2012.
60. Segura MM, Kamen AA, Garnier A. Overview of current scalable methods for purification of viral vectors. Methods Mol Biol 737:89-116, 2011.
61. Segura MM, Mangion M, Gaillet B, Garnier A. New developments in lentiviral vector design, production and purification. Expert Opin Biol Ther 13(7):987-1011, 2013.
62. Singh H, Huls H, Kebriaei P, Cooper LJ. A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. Immunol Rev 257(1):181-190, 2014.
63. Skipper KA, Andersen PR, Sharma N, Mikkelsen JG. DNA transposon-based gene vehicles - scenes from an evolutionary drive. J Biomed Sci 20:92, 2013.
64. Song XT. Combination of virotherapy and T-cell therapy: arming oncolytic virus with T-cell engagers. Discov Med 16(90):261-266, 2013.
65. Takahashi K, Yamanaka S. Induced pluripotent stem cells in medicine and biology. Development 140(12):2457-2461, 2013.
66. Vannucci L, Lai M, Chiuppesi F, Ceccherini-Nelli L, Pistello M. Viral vectors: a look back and ahead on gene transfer technology. New Microbiol 36(1):1-22, 2013.
67. Wang D, Zhong L, Nahid MA, Gao G. The potential of adeno-associated viral vectors for gene delivery to muscle tissue. Expert Opin Drug Deliv 11(3):345-364, 2014.
68. Wang W, Li W, Ma N, SteinhoffG. Non-viral gene delivery methods. Curr Pharm Biotechnol 14(1):46-60, 2013.
69. Wirth T, Parker N, Yla-Herttuala S. History of gene therapy. Gene 525(2):162-169, 2013.
70. Yanez-Munoz RJ, Balaggan KS, Macneil A, Howe SJ, Schmidt M, Smith AJ, Buch P, Maclaren RE, Anderson PN, Barker SE, Duran Y, Bartholomae C, Von Kalle C, Heckenlively JR, Kinnon C, Ali RR, Thrasher AJ. Effective gene therapy with nonintegrating lentiviral vectors. Nat Med 12(3):348-353, 2006.
71. Yang B, Li S, Wang H, Guo Y, Gessler DJ, Cao C, Su Q, Kramer J, Zhong L, Ahmed SS, Zhang H, He R, Desrosiers RC, Brown R, Xu Z, Gao G. Global CNS transduction of adult mice by intravenously delivered rAAVrh.8 and rAAVrh.10 and nonhuman primates by rAAVrh.10. Mol Ther, in press, 2014.
72. Zhang H, Yang B, Mu X, Ahmed SS, Su Q, He R, Wang H, Mueller C, Sena-Esteves M, Brown R, Xu Z, Gao G. Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol Ther 19(8):1440-1448, 2011.
73. Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L, Trono D. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 72(12):9873-9880, 1998.